Table 1.
Selected therapeutic strategies to target barriers to prostate cancer tumor immunity.
| Combination Therapies | NCT Identifier | Phase |
|---|---|---|
| May address Barrier 1: Low tumoral production of neoantigens | ||
| Sipuleucel-T and ipilumumab | NCT01804465 | 2 |
| pTVG-HP, pTVG-AR and pembrolizumab | NCT04090528 | 2 |
| PROSTVAC and nivolumab | NCT02933255 | 1/2 |
| W_pro1 and cemiplimab | NCT04382898 (PRO-MERIT) | 1/2 |
| AMG160 (PSMAxCD3 BiTE) and pembrolizumab | NCT03792841 | 1 |
| May address Barrier 2: Impaired innate immunity | ||
| Docetaxel and pembrolizumab | NCT03834506 (KEYNOTE-921) | 3 |
| Docetaxel and nivolumab | NCT04100018 (CheckMate7DX) | 3 |
| Cabozantinib and atezolizumab | NCT04446117 (CONTACT-02) | 3 |
| Olaparib and pembrolizumab | NCT03834519 (KEYLYNK-010) | 3 |
| Docetaxel, nivolumab, and ipilimumab | NCT03879122 | 2/3 |
| Rucaparib, docetaxel, enzalutamide, and nivolumab | NCT03338790 (CheckMate9KD) | 2 |
| BXCL701 (DPPi) and pembrolizumab | NCT03910660 | 1/2 |
| Fecal transplant, enzalutamide, and pembrolizumab | NCT04116775 | 2 |
| Navarixin (CXCR2i) and pembrolizumab | NCT03473925 | 2 |
| SD-101 (TLR9 agonist) and pembrolizumab | NCT03007732 | 2 |
| Bipolar androgen therapy and nivolumab | NCT03554317 (COMBAT) | 2 |
| BMS-986253 (IL8i) and nivolumab | NCT03689699 (MAGIC-8) | 1/2 |
| GB1275 (CD11b agonist) and pembrolizumab | NCT04060342 | 1/2 |
| Ipatasertib (AKTi) and atezolizumab | NCT03673787 | 1/2 |
| May address Barrier 3: Impaired T cell function | ||
| AZD4635 (A2ARi), oleclumab (anti-CD73), and durvalumab | NCT04089553 | 2 |
| AZD4635 (A2ARi), cabazitaxel, and durvalumab | NCT04495179 | 2 |
| ZEN-3694 (BETi), enzalutamide, and pembrolizumab | NCT04471974 | 2 |
| Abemaciclib (CDK4/6i) and atezolizumab | NCT04751929 | 2 |
| Etrumadenant (A2AR/A2BRi), zimberelimab, AB680 (CD73i), enzalutamide, and docetaxel | NCT04381832 (ARC-6) | 1/2 |
| Ciforadenant (A2ARi) and atezolizumab | NCT02655822 | 1 |
| Ciforadenant (A2ARi), CPI-006 (anti-CD73) and pembrolizumab | NCT03454451 | 1 |
| TPST-1120 (PPARαi) and nivolumab | NCT03829436 | 1 |
| DS3201 (EZH1/2i) and nivolumab | NCT04388852 | 1 |